Join
Live feed
·
PRReleasevia Quantisnow
Nuvectis Pharma Inc. logo

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

ByQuantisnow·Wall Street's wire, on your screen.
NVCT· Nuvectis Pharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NVCT (Nuvectis Pharma Inc.) and more on Quantisnow.